FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Mike Bray

Research Profile

Disorders

Living Beings

Chemicals & Drugs

Anatomy

Vero Cells

Physiology

Virus Replication

Procedures

Co-author Network

Publications

TOP 3
Brian B Gowen; Mike Bray
Progress in the experimental therapy of severe arenaviral infections.
Mike Bray; Shawn Babiuk
Camelpox: target for eradication?
Arthur Goff; Lisa Hensley; Eric Mucker; Mike Bray; Robert Fisher; Jolynne Raymond; Jason Paragas
Infection of cynomolgus macaques with a recombinant monkeypox virus encoding green fluorescent protein.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Mike Bray (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2011: Brian B Gowen; Mike Bray
Progress in the experimental therapy of severe arenaviral infections.
Future microbiology 2011;6(12):1429-41.
2011: Mike Bray; Shawn Babiuk
Camelpox: target for eradication?
Antiviral research 2011;92(2):164-6.
2011: Arthur Goff; Lisa Hensley; Eric Mucker; Mike Bray; Robert Fisher; Jolynne Raymond; Jason Paragas
Infection of cynomolgus macaques with a recombinant monkeypox virus encoding green fluorescent protein.
Archives of virology 2011;156(10):1877-81.
2011: Mike Bray; James Lawler; Jason Paragas; Peter B Jahrling; Daniel J Mollura
Molecular imaging of influenza and other emerging respiratory viral infections.
The Journal of infectious diseases 2011;203(10):1348-59.
2011: Mike Bray
Understanding smallpox vaccination.
The Journal of infectious diseases 2011;203(8):1037-9.
2010: Mike Bray; Michele Di Mascio; Fabian de Kok-Mercado; Daniel J Mollura; Elaine Jagoda
Radiolabeled antiviral drugs and antibodies as virus-specific imaging probes.
Antiviral research 2010;88(2):129-42.
2010: Brian B Gowen; Justin G Julander; Nyall R London; Min-Hui Wong; Deanna Larson; John D Morrey; Dean Y Li; Mike Bray
Assessing changes in vascular permeability in a hamster model of viral hemorrhagic fever.
Virology journal 2010;7():240.
2009: Peter Jahrling; Colleen Rodak; Mike Bray; Richard T Davey
Triage and management of accidental laboratory exposures to biosafety level-3 and -4 agents.
Biosecurity and bioterrorism : biodefense strategy, practice, and science 2009;7(2):135-43.
2008: John Beigel; Mike Bray
Current and future antiviral therapy of severe seasonal and avian influenza.
Antiviral research 2008;78(1):91-102.
2008: Mike Bray
Highly pathogenic RNA viral infections: challenges for antiviral research.
Antiviral research 2008;78(1):1-8.
2007: Steven M Jones; Ute Stroher; Lisa Fernando; Xianggou Qiu; Judie B Alimonti; Pasquale L Melito; Mike Bray; Hans-Dieter Klenk; Heinz Feldmann
Assessment of a vesicular stomatitis virus-based vaccine by use of the mouse model of Ebola virus hemorrhagic fever.
The Journal of infectious diseases 2007;196 Suppl 2():S404-12.
2007: Janie Parrino; Richard S Hotchkiss; Mike Bray
Prevention of immune cell apoptosis as potential therapeutic strategy for severe infections.
Emerging infectious diseases 2007;13(2):191-8.
2007: Heinz Feldmann; Steven M Jones; Kathleen M Daddario-DiCaprio; Joan B Geisbert; Ute Ströher; Allen Grolla; Mike Bray; Elizabeth A Fritz; Lisa Fernando; Friederike Feldmann; Lisa E Hensley; Thomas W Geisbert
Effective post-exposure treatment of Ebola infection.
PLoS pathogens 2007;3(1):e2.
2006: Jean-Michel Heraud; Yvette Edghill Spano; Victor Ayala; Irene Kalisz; Janie Parrino; Vaniambadi S Kalyanaraman; Jody Manischewitz; Lisa R King; Anna Hryniewicz; Christopher J Trindade; Meredith Hassett; Wen-Po Tsai; David Venzon; Aysegul Nalca; Monica Vaccari; Peter Silvera; Mike Bray; Barney S Graham; Hana Golding; Jay W Hooper; Genoveffa Franchini
Subunit recombinant vaccine protects against monkeypox.
Journal of immunology (Baltimore, Md. : 1950) 2006;177(4):2552-64.
2005: Mike Bray
Pathogenesis of viral hemorrhagic fever.
Current opinion in immunology 2005;17(4):399-403.
2005: Mike Bray; Thomas W Geisbert
Ebola virus: the role of macrophages and dendritic cells in the pathogenesis of Ebola hemorrhagic fever.
The international journal of biochemistry & cell biology 2005;37(8):1560-6.
2005: Yvette Edghill Spano; Hana Golding; Jody Manischewitz; Lisa R King; Dorothy Scott; Mike Bray; Aysegul Nalca; Jay W Hooper; Chris A Whitehouse; Joern schmitz; Keith A Reimann; Genoveffa Franchini
Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus.
Nature medicine 2005;11(7):740-7.
2005: Yvette Edghill Spano; Mike Bray; Chris A Whitehouse; David Miller; Eric Mucker; Jody Manischewitz; Lisa R King; Marjorie Robert-Guroff; Anna Hryniewicz; David Venzon; Clement A Meseda; Jerry Weir; Aysegul Nalca; Virginia Livingston; Jay Wells; Mark G Lewis; John W Huggins; Susan H Zwiers; Hana Golding; Genoveffa Franchini
Smallpox vaccine does not protect macaques with AIDS from a lethal monkeypox virus challenge.
The Journal of infectious diseases 2005;191(3):372-81.
2004: Siddhartha Mahanty; Mike Bray
Pathogenesis of filoviral haemorrhagic fevers.
The Lancet infectious diseases 2004;4(8):487-98.
2004: Mike Bray; Chad J Roy
Antiviral prophylaxis of smallpox.
The Journal of antimicrobial chemotherapy 2004;54(1):1-5.
2004: Jason Paragas; Chris A Whitehouse; Timothy Endy; Mike Bray
A simple assay for determining antiviral activity against Crimean-Congo hemorrhagic fever virus.
Antiviral research 2004;62(1):21-5.
2004: Mike Bray; Mark Buller
Looking back at smallpox.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2004;38(6):882-9.
2003: Mike Bray; Siddhartha Mahanty
Ebola hemorrhagic fever and septic shock.
The Journal of infectious diseases 2003;188(11):1613-7.
2003: Yvette Edghill Spano; David Venzon; Tatiana S Karpova; James McNally; Janos Nacsa; Wen-Po Tsai; Elzbieta Tryniszewska; Marcin Moniuszko; Jody Manischewitz; Lisa R King; Steven J Snodgrass; John Parrish; Phillip Markham; Marsha Sowers; Derrick Martin; Mark G Lewis; Jay A Berzofsky; Igor M Belyakov; Bernard Moss; Jim Tartaglia; Mike Bray; Vanessa M Hirsch; Hana Golding; Genoveffa Franchini
Modeling a safer smallpox vaccination regimen, for human immunodeficiency virus type 1-infected patients, in immunocompromised macaques.
The Journal of infectious diseases 2003;188(8):1181-91.
2003: Jenny Riemenschneider; Aura Garrison; Joan B Geisbert; Peter B Jahrling; Michael Hevey; diane negley; Alan L Schmaljohn; John Lee; Mary Kate Hart; Lorna VanderZanden; David M Custer; Mike Bray; Albert Ruff; Bruce Ivins; Anthony Bassett; Cynthia Rossi; Connie S Schmaljohn
Comparison of individual and combination DNA vaccines for B. anthracis, Ebola virus, Marburg virus and Venezuelan equine encephalitis virus.
Vaccine 2003;21(25-26):4071-80.
2003: Siddhartha Mahanty; Manisha Gupta; Jason Paragas; Mike Bray; Rafi Ahmed; Pierre E Rollin
Protection from lethal infection is determined by innate immune responses in a mouse model of Ebola virus infection.
Virology 2003;312(2):415-24.
2003: Christopher F Basler; Andrea Mikulasova; Luis Martinez-Sobrido; Jason Paragas; Elke Mühlberger; Mike Bray; Hans-Dieter Klenk; Peter Palese; Adolfo García-Sastre
The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3.
Journal of virology 2003;77(14):7945-56.
2003: Mike Bray
Pathogenesis and potential antiviral therapy of complications of smallpox vaccination.
Antiviral research 2003;58(2):101-14.
2003: Mike Bray; Mary E Wright
Progressive vaccinia.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2003;36(6):766-74.
2003: Robert O Baker; Mike Bray; John W Huggins
Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections.
Antiviral research 2003;57(1-2):13-23.
2002: Anita K McElroy; Mike Bray; Douglas S Reed; Connie S Schmaljohn
Andes virus infection of cynomolgus macaques.
The Journal of infectious diseases 2002;186(12):1706-12.
2002: Mike Bray; Jo Lynne Raymond; Tom Geisbert; Robert O Baker
3-deazaneplanocin A induces massively increased interferon-alpha production in Ebola virus-infected mice.
Antiviral research 2002;55(1):151-9.
2002: Mike Bray; Mark Martinez; Deborah Kefauver; Michael West; Chad Roy
Treatment of aerosolized cowpox virus infection in mice with aerosolized cidofovir.
Antiviral research 2002;54(3):129-42.
2002: Donald F Smee; Robert W Sidwell; Deborah Kefauver; Mike Bray; John W Huggins
Characterization of wild-type and cidofovir-resistant strains of camelpox, cowpox, monkeypox, and vaccinia viruses.
Antimicrobial agents and chemotherapy 2002;46(5):1329-35.
2002: Mike Bray; Jason Paragas
Experimental therapy of filovirus infections.
Antiviral research 2002;54(1):1-17.
2001: Donald F Smee; Mike Bray; John W Huggins
Antiviral activity and mode of action studies of ribavirin and mycophenolic acid against orthopoxviruses in vitro.
Antiviral chemistry & chemotherapy 2001;12(6):327-35.
2001: Mike Bray; S Hatfill; Lisa E Hensley; John W Huggins
Haematological, biochemical and coagulation changes in mice, guinea-pigs and monkeys infected with a mouse-adapted variant of Ebola Zaire virus.
Journal of comparative pathology 2001;125(4):243-53.
2001: T R Gibb; Mike Bray; Thomas W Geisbert; KE Steele; WM Kell; Kelly J Davis; NK Jaax
Pathogenesis of experimental Ebola Zaire virus infection in BALB/c mice.
Journal of comparative pathology 2001;125(4):233-42.
2001: Alexander G Pletnev; Mike Bray; Kathryn A Hanley; Jim Speicher; Randy Elkins
Tick-borne Langat/mosquito-borne dengue flavivirus chimera, a candidate live attenuated vaccine for protection against disease caused by members of the tick-borne encephalitis virus complex: evaluation in rhesus monkeys and in mosquitoes.
Journal of virology 2001;75(17):8259-67.
2001: JA Wilson; Mike Bray; Russell Bakken; Mary Kate Hart
Vaccine potential of Ebola virus VP24, VP30, VP35, and VP40 proteins.
Virology 2001;286(2):384-90.
2001: Donald F Smee; Mike Bray; John W Huggins
Intracellular phosphorylation of carbocyclic 3-deazaadenosine, an anti-Ebola virus agent.
Antiviral chemistry & chemotherapy 2001;12(4):251-8.
2001: Mike Bray
The role of the Type I interferon response in the resistance of mice to filovirus infection.
The Journal of general virology 2001;82(Pt 6):1365-73.
2001: Manisha Gupta; Siddhartha Mahanty; Mike Bray; Rafi Ahmed; Pierre E Rollin
Passive transfer of antibodies protects immunocompetent and imunodeficient mice against lethal Ebola virus infection without complete inhibition of viral replication.
Journal of virology 2001;75(10):4649-54.
2000: Alexander G Pletnev; Galina Karganova; T I Dzhivanyan; Vasilii A Lashkevich; Mike Bray
Chimeric Langat/Dengue viruses protect mice from heterologous challenge with the highly virulent strains of tick-borne encephalitis virus.
Virology 2000;274(1):26-31.
2000: Peter Pushko; Mike Bray; George V Ludwig; M Parker; Alan L Schmaljohn; A Sanchez; Peter B Jahrling; Jonathan F Smith
Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect guinea pigs and mice from Ebola hemorrhagic fever virus.
Vaccine 2000;19(1):142-53.
2000: JA Wilson; Michael Hevey; Russell Bakken; S Guest; Mike Bray; Alan L Schmaljohn; Mary Kate Hart
Epitopes involved in antibody-mediated protection from Ebola virus.
Science (New York, N.Y.) 2000;287(5458):1664-6.
2000: Mike Bray; M Martinez; Donald F Smee; Deborah Kefauver; E Thompson; J W Huggins
Cidofovir protects mice against lethal aerosol or intranasal cowpox virus challenge.
The Journal of infectious diseases 2000;181(1):10-9.
1999: Connie S Schmaljohn; David M Custer; Lorna VanderZanden; Kristin Spik; Cynthia Rossi; Mike Bray
Evaluation of tick-borne encephalitis DNA vaccines in monkeys.
Virology 1999;263(1):166-74.
1999: Mike Bray; K Davis; Thomas W Geisbert; Connie S Schmaljohn; John W Huggins
A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever.
The Journal of infectious diseases 1999;179 Suppl 1():S248-58.
1999: John W Huggins; Z X Zhang; Mike Bray
Antiviral drug therapy of filovirus infections: S-adenosylhomocysteine hydrolase inhibitors inhibit Ebola virus in vitro and in a lethal mouse model.
The Journal of infectious diseases 1999;179 Suppl 1():S240-7.
1999: Peter B Jahrling; Thomas W Geisbert; Joan B Geisbert; James R Swearengen; Mike Bray; NK Jaax; John W Huggins; James LeDuc; Clarence Peters
Evaluation of immune globulin and recombinant interferon-alpha2b for treatment of experimental Ebola virus infections.
The Journal of infectious diseases 1999;179 Suppl 1():S224-34.
1998: Mike Bray; K Davis; Thomas W Geisbert; Connie S Schmaljohn; John W Huggins
A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever.
The Journal of infectious diseases 1998;178(3):651-61.
1998: Ching-Juh Lai; Mike Bray; Ruhe Men; A Cahour; W Chen; H Kawano; M Tadano; K Hiramatsu; I Tokimatsu; Alexander G Pletnev; S Arakai; G Shameem; M Rinaudo
Evaluation of molecular strategies to develop a live dengue vaccine.
Clinical and diagnostic virology 1998;10(2-3):173-9.
1998: Lorna VanderZanden; Mike Bray; D Fuller; T Roberts; David M Custer; Kristin Spik; Peter B Jahrling; John W Huggins; Alan L Schmaljohn; Connie S Schmaljohn
DNA vaccines expressing either the GP or NP genes of Ebola virus protect mice from lethal challenge.
Virology 1998;246(1):134-44.
1998: Mike Bray; Ruhe Men; I Tokimatsu; Ching-Juh Lai
Genetic determinants responsible for acquisition of dengue type 2 virus mouse neurovirulence.
Journal of virology 1998;72(2):1647-51.
1997: Connie S Schmaljohn; Lorna VanderZanden; Mike Bray; David M Custer; B Meyer; D Li; Cynthia Rossi; D Fuller; J Fuller; J Haynes; John W Huggins
Naked DNA vaccines expressing the prM and E genes of Russian spring summer encephalitis virus and Central European encephalitis virus protect mice from homologous and heterologous challenge.
Journal of virology 1997;71(12):9563-9.
1996: Mike Bray; Ruhe Men; Ching-Juh Lai
Monkeys immunized with intertypic chimeric dengue viruses are protected against wild-type virus challenge.
Journal of virology 1996;70(6):4162-6.
1996: Ruhe Men; Mike Bray; D Clark; Robert M Chanock; Ching-Juh Lai
Dengue type 4 virus mutants containing deletions in the 3' noncoding region of the RNA genome: analysis of growth restriction in cell culture and altered viremia pattern and immunogenicity in rhesus monkeys.
Journal of virology 1996;70(6):3930-7.
1994: P G Livingston; Ichiro Kurane; Ching-Juh Lai; Mike Bray; Irene Bosch
Recognition of envelope protein by dengue virus serotype-specific human CD4+ CD8- cytotoxic T-cell clones.
Journal of virology 1994;68(5):3283-8.
1993: A G Pletnev; Mike Bray; Ching-Juh Lai
Chimeric tick-borne encephalitis and dengue type 4 viruses: effects of mutations on neurovirulence in mice.
Journal of virology 1993;67(8):4956-63.
1993: Alan L Rothman; Ichiro Kurane; Ching-Juh Lai; Mike Bray; B Falgout; Ruhe Men; Irene Bosch
Dengue virus protein recognition by virus-specific murine CD8+ cytotoxic T lymphocytes.
Journal of virology 1993;67(2):801-6.
1992: A G Pletnev; Mike Bray; J Huggins; Ching-Juh Lai
Construction and characterization of chimeric tick-borne encephalitis/dengue type 4 viruses.
Proceedings of the National Academy of Sciences of the United States of America 1992;89(21):10532-6.
1991: Mike Bray; Ching-Juh Lai
Construction of intertypic chimeric dengue viruses by substitution of structural protein genes.
Proceedings of the National Academy of Sciences of the United States of America 1991;88(22):10342-6.
1991: Mike Bray; Ching-Juh Lai
Dengue virus premembrane and membrane proteins elicit a protective immune response.
Virology 1991;185(1):505-8.
1991: Ching-Juh Lai; B T Zhao; H Hori; Mike Bray
Infectious RNA transcribed from stably cloned full-length cDNA of dengue type 4 virus.
Proceedings of the National Academy of Sciences of the United States of America 1991;88(12):5139-43.
1991: Ruhe Men; Mike Bray; Ching-Juh Lai
Carboxy-terminally truncated dengue virus envelope glycoproteins expressed on the cell surface and secreted extracellularly exhibit increased immunogenicity in mice.
Journal of virology 1991;65(3):1400-7.
1990: B Falgout; Mike Bray; J J Schlesinger; Ching-Juh Lai
Immunization of mice with recombinant vaccinia virus expressing authentic dengue virus nonstructural protein NS1 protects against lethal dengue virus encephalitis.
Journal of virology 1990;64(9):4356-63.
1989: J F Bukowski; Ichiro Kurane; Ching-Juh Lai; Mike Bray; B Falgout; Irene Bosch
Dengue virus-specific cross-reactive CD8+ human cytotoxic T lymphocytes.
Journal of virology 1989;63(12):5086-91.
1989: Mike Bray; B T Zhao; L Markoff; Kenneth H Eckels; Robert M Chanock; Ching-Juh Lai
Mice immunized with recombinant vaccinia virus expressing dengue 4 virus structural proteins with or without nonstructural protein NS1 are protected against fatal dengue virus encephalitis.
Journal of virology 1989;63(6):2853-6.